| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 155 | 2019 |
| Management of metastatic clear cell renal cell carcinoma: ASCO guideline WK Rathmell, RB Rumble, PJ Van Veldhuizen, H Al-Ahmadie, ... Journal of Clinical Oncology 40 (25), 2957-2995, 2022 | 139 | 2022 |
| Multicenter prospective phase II trial of neoadjuvant dose-dense gemcitabine plus cisplatin in patients with muscle-invasive bladder cancer G Iyer, AV Balar, MI Milowsky, BH Bochner, G Dalbagni, SM Donat, ... Journal of clinical oncology 36 (19), 1949, 2018 | 124 | 2018 |
| Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience TL Rose, WH Weir, GM Mayhew, Y Shibata, P Eulitt, JM Uronis, M Zhou, ... British journal of cancer 125 (9), 1251-1260, 2021 | 86 | 2021 |
| Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer TL Rose, MR Harrison, AM Deal, S Ramalingam, YE Whang, B Brower, ... Journal of Clinical Oncology 39 (28), 3140, 2021 | 82 | 2021 |
| Optimized management of nivolumab and ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE) RR McKay, BA McGregor, W Xie, DA Braun, X Wei, CE Kyriakopoulos, ... Journal of clinical oncology 38 (36), 4240, 2020 | 74 | 2020 |
| Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer TL Rose, AM Deal, ME Nielsen, AB Smith, MI Milowsky Cancer 122 (13), 2012-2020, 2016 | 59 | 2016 |
| Intrinsic genomic differences between African American and white patients with clear cell renal cell carcinoma B Krishnan, TL Rose, J Kardos, MI Milowsky, WY Kim JAMA oncology 2 (5), 664-667, 2016 | 57 | 2016 |
| Entinostat induces antitumor immune responses through immune editing of tumor neoantigens AS Truong, M Zhou, B Krishnan, T Utsumi, U Manocha, KG Stewart, ... The Journal of Clinical Investigation 131 (16), 2021 | 54 | 2021 |
| Improving systemic chemotherapy for bladder cancer TL Rose, MI Milowsky Current oncology reports 18, 1-12, 2016 | 43 | 2016 |
| Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial … AV Balar, MI Milowsky, PH O'Donnell, AS Alva, M Kollmeier, TL Rose, ... Journal of Clinical Oncology 39 (15_suppl), 4504-4504, 2021 | 38 | 2021 |
| Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era TL Rose, AM Deal, B Krishnan, ME Nielsen, AB Smith, WY Kim, ... Cancer 122 (19), 2988-2995, 2016 | 38 | 2016 |
| Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy TL Rose, DD Chism, AS Alva, AM Deal, SJ Maygarden, YE Whang, ... British Journal of Cancer 119 (7), 801-807, 2018 | 30 | 2018 |
| A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy TK Choueiri, MB Atkins, TL Rose, RS Alter, Y Ju, K Niland, Y Wang, ... Investigational New Drugs 39, 1019-1027, 2021 | 28 | 2021 |
| Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity JD Sorah, TL Rose, R Radhakrishna, VK Derebail, MI Milowsky Journal of Immunotherapy 44 (3), 127-131, 2021 | 24 | 2021 |
| Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). RR McKay, W Xie, BA McGregor, DA Braun, XX Wei, C Kyriakopoulos, ... Journal of Clinical Oncology 38 (15_suppl), 5005-5005, 2020 | 24 | 2020 |
| Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: an evaluation of transitions between academic and community settings TL Rose, AM Deal, E Basch, PA Godley, WK Rathmell, WY Kim, ... Urologic Oncology: Seminars and Original Investigations 33 (9), 386. e1-386. e6, 2015 | 18 | 2015 |
| Patterns of bladder preservation therapy utilization for muscle-invasive bladder cancer TL Rose, AM Deal, S Ladoire, G Créhange, MD Galsky, JE Rosenberg, ... Bladder Cancer 2 (4), 405-413, 2016 | 17 | 2016 |
| Pilot study of [18F] fluorodeoxyglucose positron emission tomography (FDG-PET)/magnetic resonance imaging (MRI) for staging of muscle-invasive bladder cancer (MIBC) PJ Eulitt, E Altun, A Sheikh, TZ Wong, ME Woods, TL Rose, EM Wallen, ... Clinical genitourinary cancer 18 (5), 378-386. e1, 2020 | 16 | 2020 |
| Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer TL Rose, Y Lotan Urologic Oncology: Seminars and Original Investigations 36 (3), 97-102, 2018 | 16 | 2018 |
